- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Contact Dermatitis: Expert Insights on First-Line and Emerging Therapies
JiaDe 'Jeff' Yu, MD, discusses first-line therapies, emerging biologics, and the potential of molecular biomarkers for improved diagnosis.
In an interview with Patient Care© Online at the 2025 American Academy of Dermatology Annual Meeting, JiaDe 'Jeff' Yu, MD, a dermatologist at Massachusetts General Hospital in Boston, shared valuable insights on managing contact dermatitis for primary care physicians. In the video above, Dr Yu shares his recommendations on first-line treatment options and insights into emerging research, including the potential use of molecular biomarkers to improve diagnosis.
Dr Yu is the director of the Contact Dermatitis Clinic at Massachusetts General Hospital and assistant professor at Harvard Medical School in Boston.
For more of our conversation with Dr Yu, check out:
- Recognizing Allergic Contact Dermatitis in Children: Expert Pearls at AAD 2025
- JiaDe Yu, MD: Key Signs of Allergic Contact Dermatitis in Children
Kymera's Oral STAT6 Degrader KT-621 Shows Biologic-Like Activity in Early Atopic Dermatitis Trial
December 8th 2025KT-621 achieved deep STAT6 degradation and strong 4-week EASI and itch reductions, offering a potential new oral option for moderate–severe AD and other Th2 inflammation-driven disease.
